Information Provided By: 
Fly News Breaks for July 11, 2018
OCX
Jul 11, 2018 | 08:22 EDT
Benchmark analyst Bruce Jackson assumed coverage of OncoCyte with a Buy rating and $7 price target, stating that he sees a "clear pathway to commercial availability" for its blood-based lung cancer test, which he believes can prevent the need for risky and expensive lung tissue biopsy procedures. The stock was previously covered by Raymond Myers, who'd had a Speculative Buy rating on OncoCyte.
News For OCX From the Last 2 Days
OCX
Apr 15, 2024 | 10:45 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: OncoCyte (OCX),... To see the rest of the story go to thefly.com. See Story Here
